Etanercept: An overview - 29/08/11
Doi : 10.1016/mjd.2003.554
Ben Goffe, MD a, ⁎ 
, Jennifer Clay Cather, MD b, c
, Jennifer Clay Cather, MD b, c a Department of Dermatology, University of Washington, Seattle, Washington, USA
b Texas Dermatology Associates, Dallas, Texas, USA
c Baylor University Medical Center, Dallas, Texas, USA
*Reprint requests: Ben Goffe, MD, University of Washington, Clinical Professor, Minor-James Medical-Dermatology, 515 Minor Ave, Ste 200, Seattle, WA 98104, USA
Abstract |
Etanercept, a competitive inhibitor of TNF-⍺, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
Il testo completo di questo articolo è disponibile in PDF.Mappa
 | Funding sources: None. Disclosure: Drs Cather and Goffe have participated in clinical trials involving Enbrel. Dr Goffe is involved in trials funded by Immunex (now Amgen), Biogen, Genentech, Corixa, IDEC, Boehringer-Ingelheim, ISIS, Fujisawa, and Bristol Meyers. Dr Goffe is on the speaker’s bureau for Amgen; however, he is not a paid consultant. |
© 2003
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 49 - N° 2S
P. 105-111 - agosto 2003 Ritorno al numero
Articolo precedente
- Efalizumab: an overview
- Craig L Leonardi
- Infliximab for psoriasis
- Alice B Gottlieb
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?